12 results on '"Marsh, Nicole"'
Search Results
2. Idle peripheral intravenous cannulation: an observational cohort study of pre-hospital and emergency department practices
- Author
-
Evison, Hugo, Sweeny, Amy, Ranse, Jamie, Carrington, Mercedes, Marsh, Nicole, Byrnes, Joshua, Rickard, Claire M., Carr, Peter J., and Keijzers, Gerben
- Published
- 2021
- Full Text
- View/download PDF
3. Risk factors for arterial catheter failure and complications during critical care hospitalisation: a secondary analysis of a multisite, randomised trial.
- Author
-
Schults, Jessica A., Young, Emily R., Marsh, Nicole, Larsen, Emily, Corley, Amanda, Ware, Robert S., Murgo, Marghie, Alexandrou, Evan, McGrail, Matthew, Gowardman, John, Charles, Karina R., Regli, Adrian, Yasuda, Hideto, and Rickard, Claire M.
- Subjects
ARTERIAL catheters ,SECONDARY analysis ,INTENSIVE care patients ,CATHETER-related infections ,CRITICAL care medicine ,SECONDARY care (Medicine) - Abstract
Objectives: Arterial catheters (ACs) are critical for haemodynamic monitoring and blood sampling but are prone to complications. We investigated the incidence and risk factors of AC failure. Methods: Secondary analysis of a multi-centre randomised controlled trial (ACTRN 12610000505000). Analysis included a subset of adult intensive care unit patients with an AC. The primary outcome was all-cause device failure. Secondary outcomes were catheter associated bloodstream infection (CABSI), suspected CABSI, occlusion, thrombosis, accidental removal, pain, and line fracture. Risk factors associated with AC failure were investigated using Cox proportional hazards and competing-risk models. Results: Of 664 patients, 173 (26%) experienced AC failure (incidence rate [IR] 37/1000 catheter days). Suspected CABSI was the most common failure type (11%; IR 15.3/1000 catheter days), followed by occlusion (8%; IR 11.9/1,000 catheter days), and accidental removal (4%; IR 5.5/1000 catheter days). CABSI occurred in 16 (2%) patients. All-cause failure and occlusion were reduced with ultrasound-assisted insertion (failure: adjusted hazard ratio [HR] 0.43, 95% CI 0.25, 0.76; occlusion: sub-HR 0.11, 95% CI 0.03, 0.43). Increased age was associated with less AC failure (60–74 years HR 0.63, 95% CI 0.44 to 0.89; 75 + years HR 0.36, 95% CI 0.20, 0.64; referent 15–59 years). Females experienced more occlusion (adjusted sub-HR 2.53, 95% CI 1.49, 4.29), while patients with diabetes had less (SHR 0.15, 95% CI 0.04, 0.63). Suspected CABSI was associated with an abnormal insertion site appearance (SHR 2.71, 95% CI 1.48, 4.99). Conclusions: AC failure is common with ultrasound-guided insertion associated with lower failure rates. Trial registration Australian New Zealand Clinical Trial Registry (ACTRN 12610000505000); date registered: 18 June 2010. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. A comparison of hydrophobic polyurethane and polyurethane peripherally inserted central catheter: results from a feasibility randomized controlled trial
- Author
-
Gavin, Nicole C., Kleidon, Tricia M., Larsen, Emily, O’Brien, Catherine, Ullman, Amanda, Northfield, Sarah, Mihala, Gabor, Runnegar, Naomi, Marsh, Nicole, and Rickard, Claire M.
- Published
- 2020
- Full Text
- View/download PDF
5. Implementation and evaluation of short peripheral intravenous catheter flushing guidelines: a stepped wedge cluster randomised trial
- Author
-
Keogh, Samantha, Shelverton, Caroline, Flynn, Julie, Mihala, Gabor, Mathew, Saira, Davies, Karen M., Marsh, Nicole, and Rickard, Claire M.
- Published
- 2020
- Full Text
- View/download PDF
6. Health-related quality of life and experience measures, to assess patients' experiences of peripheral intravenous catheters: a secondary data analysis.
- Author
-
Larsen, Emily N., Marsh, Nicole, Rickard, Claire M., Mihala, Gabor, Walker, Rachel M., and Byrnes, Joshua
- Subjects
- *
PATIENTS' attitudes , *QUALITY of life , *SECONDARY analysis , *PATIENT experience , *PATIENT satisfaction - Abstract
Background: Peripheral intravenous catheters (PIVCs) are essential for successful administration of intravenous treatments. However, insertion failure and PIVC complications are common and negatively impact patients' health-outcomes and experiences. We aimed to assess whether generic (not condition-specific) quality of life and experience measures were suitable for assessing outcomes and experiences of patients with PIVCs. Methods: We undertook a secondary analysis of data collected on three existing instruments within a large randomised controlled trial, conducted at two adult tertiary hospitals in Queensland, Australia. Instruments included the EuroQol Five Dimension - Five Level (EQ5D-5L), the Functional Assessment of Chronic Illness Therapy – Treatment Satisfaction – General measure (FACIT-TS-G, eight items), and the Australian Hospital Patient Experience Question Set (AHPEQS, 12 items). Responses were compared against two clinical PIVC outcomes of interest: all-cause failure and multiple insertion attempts. Classic descriptives were reported for ceiling and floor effects. Regression analyses examined validity (discrimination). Standardised response mean and effect size (ES) assessed responsiveness (EQ5D-5L, only). Results: In total, 685 participants completed the EQ5D-5L at insertion and 526 at removal. The FACIT-TS-G was completed by 264 and the AHPEQS by 262 participants. Two FACIT-TS-G items and one AHPEQS item demonstrated ceiling effect. Instruments overall demonstrated poor discrimination, however, all-cause PIVC failure was significantly associated with several individual items in the instruments (e.g., AHPEQS, 'unexpected physical and emotional harm'). EQ5D-5L demonstrated trivial (ES < 0.20) responsiveness. Conclusions: Initial investigation of an existing health-related quality of life measure (EQ5D-5L) and two patient-reported experience measures (FACIT-TS-G; AHPEQS) suggest they are inadequate (as a summary measure) to assess outcomes and experiences for patients with PIVCs. Reliable instruments are urgently needed to inform quality improvement and benchmark standards of care. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Improving difficult peripheral intravenous access requires thought, training and technology (DART3): a stepped-wedge, cluster randomised controlled trial protocol.
- Author
-
Schults, Jessica A, Marsh, Nicole, Ullman, Amanda J, Kleidon, Tricia M, Ware, Robert S, Byrnes, Joshua, Young, Emily, Hall, Lisa, Keijzers, Gerben, Cullen, Louise, Calleja, Pauline, McTaggart, Steven, Peters, Nathan, Watkins, Stuart, Corley, Amanda, Brown, Christine, Lin, Zhen, Williamson, Frances, Burgess, Luke, and Macfarlane, Fiona
- Subjects
- *
CLUSTER randomized controlled trials , *TREATMENT delay (Medicine) - Abstract
Background: Peripheral intravenous catheters (PIVCs) are the most used invasive medical device in healthcare. Yet around half of insertion attempts are unsuccessful leading to delayed medical treatments and patient discomfort of harm. Ultrasound-guided PIVC (USGPIVC) insertion is an evidence-based intervention shown to improve insertion success especially in patients with Difficult IntraVenous Access (BMC Health Serv Res 22:220, 2022), however the implementation in some healthcare settings remains suboptimal. This study aims to co-design interventions that optimise ultrasound guided PIVC insertion in patients with DIVA, implement and evaluate these initiatives and develop scale up activities. Methods: A stepped-wedge cluster randomized controlled trial will be conducted in three hospitals (two adult, one paediatric) in Queensland, Australia. The intervention will be rolled out across 12 distinct clusters (four per hospital). Intervention development will be guided by Michie's Behavior Change Wheel with the aim to increase local staff capability, opportunity, and motivation for appropriate, sustainable adoption of USGPIVC insertion. Eligible clusters include all wards or departments where > 10 PIVCs/week are typically inserted. All clusters will commence in the control (baseline) phase, then, one cluster per hospital will step up every two months, as feasible, to the implementation phase, where the intervention will be rolled out. Implementation strategies are tailored for each hospital by local investigators and advisory groups, through context assessments, staff surveys, and stakeholder interviews and informed by extensive consumer interviews and consultation. Outcome measures align with the RE-AIM framework including clinical-effectiveness outcomes (e.g., first-time PIVC insertion success for DIVA patients [primary outcome], number of insertion attempts); implementation outcomes (e.g., intervention fidelity, readiness assessment) and cost effectiveness outcomes. The Consolidated Framework for Implementation Research framework will be used to report the intervention as it was implemented; how people participated in and responded to the intervention; contextual influences and how the theory underpinning the intervention was realised and delivered at each site. A sustainability assessment will be undertaken at three- and six-months post intervention. Discussion: Study findings will help define systematic solutions to implement DIVA identification and escalation tools aiming to address consumer dissatisfaction with current PIVC insertion practices. Such actionable knowledge is critical for implementation of scale-up activities. Trial registration: Prospectively registered (Australian and New Zealand Clinical Trials Registry; ACTRN12621001497897). [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. A novel integrated dressing to secure peripheral intravenous catheters in an adult acute hospital: a pilot randomised controlled trial
- Author
-
Marsh, Nicole, Larsen, Emily, Genzel, Jodie, Mihala, Gabor, Ullman, Amanda J., Kleidon, Tricia, Cadigan, Sue, and Rickard, Claire M.
- Published
- 2018
- Full Text
- View/download PDF
9. Expert versus generalist inserters for peripheral intravenous catheter insertion: a pilot randomised controlled trial
- Author
-
Marsh, Nicole, Webster, Joan, Larsen, Emily, Genzel, Jodie, Cooke, Marie, Mihala, Gabor, Cadigan, Sue, and Rickard, Claire M
- Published
- 2018
- Full Text
- View/download PDF
10. Expert versus generalist inserters for peripheral intravenous catheter insertion: a pilot randomised controlled trial.
- Author
-
Cadigan, Sue, Marsh, Nicole, Larsen, Emily, Genzel, Jodie, Rickard, Claire M, Webster, Joan, Cooke, Marie, and Mihala, Gabor
- Subjects
- *
CATHETERS , *INSERTION reactions (Chemistry) , *PATIENTS , *HOSPITALS , *FEASIBILITY studies - Abstract
Background: Peripheral intravenous catheters (PVCs) are essential invasive devices, with 2 billion PVCs sold each year. The comparative efficacy of expert versus generalist inserter models for successful PVC insertion and subsequent reliable vascular access is unknown.Methods: A single-centre, parallel-group, pilot randomised controlled trial (RCT) of 138 medical/surgical patients was conducted in a large tertiary hospital in Australia to compare PVC insertion by (1) a vascular access specialist (VAS) or (2) any nursing or medical clinician (generalist model). The primary outcome was the feasibility of a larger RCT as established by predetermined criteria (eligibility, recruitment, retention, protocol adherence). Secondary outcomes were PVC failure: phlebitis, infiltration/extravasation, occlusion, accidental removal or partial dislodgement, local infection or catheter-related bloodstream infection; dwell time; insertion success, insertion attempts; patient satisfaction; and procedural cost-effectiveness.Results: Feasibility outcomes were achieved: 92% of screened patients were eligible; two patients refused participation; there was no attrition or missing outcome data. PVC failure was higher with generalists (27/50, 54%) than with VASs (33/69, 48%) (228 versus 217 per 1000 PVC days; incidence rate ratio 1.05, 95% confidence interval 0.61-1.80). There were no local or PVC-related infections in either group. All PVCs (n = 69) were successfully inserted in the VAS group. In the generalist group, 19 (28%) patients did not have a PVC inserted. There were inadequate data available for the cost-effectiveness analysis, but the mean insertion procedure time was 2 min in the VAS group and 11 min in the generalist group. Overall satisfaction with the PVC was measured on an 11-point scale (0 = not satisfied and 10 = satisfied) and was higher in the VAS group (n = 43; median = 7) compared to the generalist group (n = 20; median = 4.5). The multivariable model identified medical diagnosis and bed-bound status as being significantly associated with higher PVC failure, and securement with additional non-sterile tape was significantly associated with lower PVC failure.Conclusion: This pilot trial confirmed the feasibility and need for a large, multicentre RCT to test these PVC insertion models.Trial Registration: Australian New Zealand Clinical Trials Registry, ACTRN12616001675415 . Registered on 6 December 2016. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
11. Central venous Access device SeCurement And Dressing Effectiveness for peripherally inserted central catheters in adult acute hospital patients (CASCADE): a pilot randomised controlled trial.
- Author
-
Chan, Raymond J., Northfield, Sarah, Larsen, Emily, Mihala, Gabor, Ullman, Amanda, Hancock, Peter, Marsh, Nicole, Gavin, Nicole, Wyld, David, Allworth, Anthony, Russell, Emily, Choudhury, Md Abu, Flynn, Julie, and Rickard, Claire M.
- Subjects
CATHETER-related infections ,PERIPHERALLY inserted central catheters ,PERIPHERAL central venous catheterization ,SURGICAL dressings ,NOSOCOMIAL infections ,BACTERICIDES ,ADHESIVES in surgery ,ATTITUDE (Psychology) ,CATHETERS ,CHLORHEXIDINE ,COMPARATIVE studies ,HOSPITAL patients ,INTRAVENOUS catheterization ,RESEARCH methodology ,MEDICAL cooperation ,MEDICAL personnel ,PATIENT satisfaction ,POLYURETHANES ,RESEARCH ,TIME ,PILOT projects ,PRODUCT design ,EVALUATION research ,RANDOMIZED controlled trials ,TREATMENT effectiveness ,CENTRAL venous catheterization ,MEDICAL equipment reliability ,MEDICAL device removal ,CENTRAL venous catheters ,EQUIPMENT & supplies ,DIAGNOSIS ,THERAPEUTICS ,INFECTION prevention - Abstract
Background: Peripherally inserted central catheters (PICCs) are commonly used for delivering intravenous therapy. PICC failure is unacceptably high (up to 40%) due to mechanical, infectious and thrombotic complications. Poor securement potentiates all complication types. This randomised controlled trial (RCT) aimed to examine the feasibility of a large RCT of four dressing and securement methods to prevent PICC failure.Methods: This single-centre pilot RCT included 124 admitted medical/surgical/cancer patients aged ≥ 16 years with a PICC. Interventions were: (i) standard polyurethane dressing and sutureless securement device (SPU + SSD, control); (ii) polyurethane with absorbent lattice pad dressing (PAL + Tape); (iii) combination securement-dressing (CSD); and (iv) tissue adhesive (TA + SPU). All groups except TA + SPU had a chlorhexidine-gluconate (CHG) impregnated disc. Feasibility outcomes were recruitment and safety/acceptability of the interventions. The primary outcome was PICC failure, a composite of PICC removal for local infection, catheter-associated bloodstream infection, dislodgement, occlusion, and/or catheter fracture. Secondary outcomes included individual complications, dressing failure and dwell time, PICC dwell time, skin complications/phlebitis indicators, product costs, and patient and staff satisfaction. Qualitative feedback was also collected.Results: PICC failure incidence was: PAL + CHG + Tape (1/5; 20%; 17.4/1000 days), SPU + SSD + CHG (control) (4/39; 10%; 9.0/1000 days), TA + SPU (3/35; 9%; 9.6/1000 days), and CSD + CHG (3/42; 7%; 9.4/1000 days). Recruitment to PAL + CHG + Tape was ceased after five participants due to concerns of PICC dislodgement when removing the dressing. CSD + CHG, TA + SPU (TA applied only at PICC insertion time), and control treatments were acceptable to patients and health professionals.Conclusion: A large RCT of CSD + CHG and TA + SPU (but not PAL + CHG + Tape) versus standard care is feasible.Trial Registration: Australian and New Zealand Clinical Trials Registry, ACTRN12616000027415 . Registered on 15 January 2016. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
12. Varied flushing frequency and volume to prevent peripheral intravenous catheter failure: a pilot, factorial randomised controlled trial in adult medical-surgical hospital patients.
- Author
-
Keogh, Samantha, Flynn, Julie, Marsh, Nicole, Mihala, Gabor, Davies, Karen, and Rickard, Claire
- Subjects
INTRAVENOUS catheterization complications ,VASCULAR endothelium ,HEALTH outcome assessment ,PHLEBITIS ,SURGICAL hospitals ,ARTERIAL occlusions ,HEALTH of adults ,RANDOMIZED controlled trials ,PREVENTION ,BLOOD vessels ,CATHETERS ,COMPARATIVE studies ,INTRAVENOUS catheterization ,IRRIGATION (Medicine) ,RESEARCH methodology ,MEDICAL cooperation ,MEDICAL equipment ,RESEARCH ,SALT ,SEX distribution ,TIME ,PILOT projects ,EVALUATION research ,SPECIALTY hospitals ,TREATMENT effectiveness ,PROPORTIONAL hazards models ,MEDICAL equipment reliability ,KAPLAN-Meier estimator ,EQUIPMENT & supplies - Abstract
Background: Research has identified high failure rates of peripheral intravenous catheter (PIVC) and varied flushing practices.Methods: This is a single-centre, pilot, non-masked, factorial randomised controlled trial. Participants were adults, with a PIVC of expected use ≥24 hours (n = 160), admitted to general medical or surgical wards of a tertiary referral hospital in Queensland (Australia). Patients were randomly allocated to one of four flush groups using manually prepared syringes and 0.9 % sodium chloride: 10 mL or 3 mL flush, every 24 or 6 hours. The primary endpoint was PIVC failure, a composite measure of occlusion, infiltration, accidental dislodgement and phlebitis.Results: PIVC average dwell was 3.1 days. PIVC failure rates per 1000 hours were not significantly different for the volume intervention (4.84 [3 mL] versus 7.44 [10 mL], p = 0.06, log-rank). PIVC failure rates per 1000 hours were also not significantly different for the frequency intervention (5.06 [24 hour] versus 7.34 [6 hour], p = 0.05, log-rank). Cox proportional hazard regression found neither the flushing nor frequency intervention, or their interaction (p = 0.21) to be significantly associated with PIVC failure. However, female gender (hazard ratio [HR] 2.2 [1.3-3.6], p < 0.01), insertion in hand/posterior wrist (HR 1.7 [1.0-2.7], p < 0.05) and the rate per day of PIVC access (combined flushes and medication pushes) (HR 1.2 [1.1-1.4], p < 0.01) significantly predicted PIVC failure.Conclusion: Neither increased flushing volume nor frequency significantly altered the risk of PIVC failure. Female gender, hand/posterior wrist placement and episodes of access (flushes and medication) may be more important. Larger, definitive trials are feasible and required.Trial Registration: Australian and New Zealand Clinical Trials Registry: ACTRN12615000025538 . Registered on 19 January 2015. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.